Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

Clare P. Herd; Claire L. Tomlinson; Katherine H. O. Deane; Marian C. Brady; Christina H. Smith; Catherine M. Sackley; Carl E. Clarke

doi:10.1002/14651858.CD002812.pub2

Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

Clare P. Herd
, Claire L. Tomlinson
, Katherine H. O. Deane
, Marian C. Brady
, Christina H. Smith
, Catherine M. Sackley
, Carl E. Clarke

Research output: Contribution to journal › Article › peer-review

50 Citations (Scopus)

19 Downloads (Pure)

Abstract

Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

Original language	English
Article number	CD002812
Journal	Cochrane Database of Systematic Reviews
Volume	8
DOIs	https://doi.org/10.1002/14651858.CD002812.pub2
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Randomized Controlled Trials as Topic
Watchful Waiting
Parkinson Disease
Speech Intelligibility
Humans
Dysarthria
Speech Therapy
Language Therapy

Access to Document

10.1002/14651858.CD002812.pub2

Herd-2012-Speech and languageFinal published version, 401 KB

Cite this

@article{3b2d93d14c4c45d89bb1bfbc591b5c52,

title = "Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease",

abstract = "Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.",

keywords = "Randomized Controlled Trials as Topic, Watchful Waiting, Parkinson Disease, Speech Intelligibility, Humans, Dysarthria, Speech Therapy, Language Therapy",

author = "Herd, \{Clare P.\} and Tomlinson, \{Claire L.\} and Deane, \{Katherine H. O.\} and Brady, \{Marian C.\} and Smith, \{Christina H.\} and Sackley, \{Catherine M.\} and Clarke, \{Carl E.\}",

year = "2012",

doi = "10.1002/14651858.CD002812.pub2",

language = "English",

volume = "8",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "Wiley",

}

TY - JOUR

T1 - Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease

AU - Herd, Clare P.

AU - Tomlinson, Claire L.

AU - Deane, Katherine H. O.

AU - Brady, Marian C.

AU - Smith, Christina H.

AU - Sackley, Catherine M.

AU - Clarke, Carl E.

PY - 2012

Y1 - 2012

N2 - Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

AB - Parkinson's disease patients commonly suffer from speech and vocal problems including dysarthric speech, reduced loudness and loss of articulation. These symptoms increase in frequency and intensity with progression of the disease). Speech and language therapy (SLT) aims to improve the intelligibility of speech with behavioural treatment techniques or instrumental aids.

KW - Randomized Controlled Trials as Topic

KW - Watchful Waiting

KW - Parkinson Disease

KW - Speech Intelligibility

KW - Humans

KW - Dysarthria

KW - Speech Therapy

KW - Language Therapy

U2 - 10.1002/14651858.CD002812.pub2

DO - 10.1002/14651858.CD002812.pub2

M3 - Article

C2 - 22895930

SN - 1465-1858

VL - 8

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

M1 - CD002812

ER -